Spyre Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Spyre Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q3 2024.
  • Spyre Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$55.4M, a 202% decline year-over-year.
  • Spyre Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$193M, a 10.4% increase year-over-year.
  • Spyre Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$242M, a 186% decline from 2022.
  • Spyre Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$84.8M, a 29.1% decline from 2021.
  • Spyre Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$65.6M, a 19.4% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$193M -$55.4M -$37.1M -202% Jul 1, 2024 Sep 30, 2024 10-Q/A 2024-11-18
Q2 2024 -$156M -$44.1M +$115M +72.3% Apr 1, 2024 Jun 30, 2024 10-Q/A 2024-11-18
Q1 2024 -$271M -$47.8M -$29M -154% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-11-18
Q4 2023 -$242M -$45.9M -$26.8M -140% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-11-18
Q3 2023 -$216M -$18.3M +$418K +2.23% Jul 1, 2023 Sep 30, 2023 10-Q/A 2024-11-18
Q2 2023 -$216M -$159M -$137M -610% Apr 1, 2023 Jun 30, 2023 10-Q/A 2024-11-18
Q1 2023 -$79.1M -$18.8M +$5.64M +23.1% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-11-18
Q4 2022 -$84.8M -$19.2M +$1.28M +6.26% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-11-18
Q3 2022 -$86.1M -$18.8M +$1.54M +7.58% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$87.6M -$22.4M -$15.7M -234% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$71.9M -$24.4M -$6.23M -34.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$65.6M -$20.4M +$2.33M +10.2% Oct 1, 2021 Dec 31, 2021 10-K/A 2024-11-18
Q3 2021 -$68M -$20.3M -$2.17M -12% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$65.8M -$6.71M +$14.9M +68.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$80.7M -$18.2M +$813K +4.27% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$81.5M -$22.8M -$867K -3.96% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-18
Q3 2020 -$80.6M -$18.1M +$4.02M +18.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$84.6M -$21.6M -$2.94M -15.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$81.7M -$19M -$1.37M -7.73% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$80.3M -$21.9M -$6.6M -43.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$73.7M -$22.1M -$9.9M -80.9% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-18
Q2 2019 -$63.8M -$18.6M -$8.95M -92.6% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-18
Q1 2019 -$54.9M -$17.7M -$9.41M -114% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-18
Q4 2018 -$45.5M -$15.3M -$8.68M -131% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 -$36.8M -$12.2M -$4.25M -53.1% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-24
Q2 2018 -$32.5M -$9.67M -$2.95M -43.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-24
Q1 2018 -$29.6M -$8.25M -$1.91M -30.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-24
Q4 2017 -$27.7M -$6.63M -$1.08M -19.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$26.6M -$8M -$1.7M -26.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$24.9M -$6.72M -$1.23M -22.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$23.7M -$6.33M -$1.76M -38.6% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$21.9M -$5.54M -$1.55M -38.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-13
Q3 2016 -$20.4M -$6.3M -$2.88M -84.4% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-13
Q2 2016 -$17.5M -$5.5M -$4.06M -284% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-13
Q1 2016 -$13.4M -$4.57M -$2.1M -85% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-13
Q4 2015 -$11.3M -$4M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-23
Q3 2015 -$3.42M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-23
Q2 2015 -$1.43M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-23
Q1 2015 -$2.47M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.